S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
S&P 500   4,691.25 (+2.17%)
DOW   35,754.77 (+1.50%)
QQQ   397.73 (+2.99%)
AAPL   171.19 (+3.55%)
MSFT   335.64 (+2.90%)
FB   324.28 (+2.02%)
GOOGL   2,940.43 (+2.70%)
AMZN   3,528.79 (+2.96%)
TSLA   1,043.33 (+3.40%)
NVDA   320.07 (+6.56%)
BABA   125.59 (+1.61%)
NIO   33.31 (+3.00%)
CGC   10.86 (+7.00%)
AMD   144.63 (+4.01%)
GE   98.00 (+2.07%)
MU   86.83 (+5.31%)
T   23.13 (-0.64%)
F   19.91 (+3.59%)
DIS   150.46 (+0.06%)
PFE   51.27 (-0.41%)
AMC   31.38 (+9.00%)
ACB   6.40 (+7.20%)
BA   210.77 (+2.38%)
NASDAQ:ICPT

Intercept Pharmaceuticals Stock Forecast, Price & News

$17.39
+1.21 (+7.48%)
(As of 12/7/2021 12:50 PM ET)
Add
Compare
Today's Range
$16.61
$17.48
50-Day Range
$14.38
$19.53
52-Week Range
$11.60
$38.94
Volume
12,953 shs
Average Volume
966,875 shs
Market Capitalization
$513.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44
30 days | 90 days | 365 days | Advanced Chart
Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ICPT
CUSIP
45845P10
Employees
498
Year Founded
N/A

Sales & Book Value

Annual Sales
$312.69 million
Book Value
($5.28) per share

Profitability

Net Income
$-274.88 million
Pretax Margin
-30.28%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,544,000
Market Cap
$513.82 million
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.41 out of 5 stars

Medical Sector

185th out of 1,394 stocks

Pharmaceutical Preparations Industry

76th out of 673 stocks

Analyst Opinion: 3.1Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

Is Intercept Pharmaceuticals a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 10 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals
or view top-rated stocks.

How has Intercept Pharmaceuticals' stock been impacted by Coronavirus?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICPT stock has decreased by 77.8% and is now trading at $17.23.
View which stocks have been most impacted by COVID-19
.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Intercept Pharmaceuticals
.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) posted its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.00) by $0.89. The biopharmaceutical company had revenue of $92.80 million for the quarter, compared to analysts' expectations of $83.04 million. The business's quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.01) EPS.
View Intercept Pharmaceuticals' earnings history
.

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $355 million-$370 million, compared to the consensus revenue estimate of $339.04 million.

What price target have analysts set for ICPT?

17 brokers have issued 12 month price objectives for Intercept Pharmaceuticals' shares. Their forecasts range from $10.00 to $67.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 72.2% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Jerome B. Durso, President, Chief Executive Officer & Director
  • Andrew Saik, Chief Financial Officer
  • M. Michelle Berrey, Chief Medical Officer
  • Linda M. Richardson, Chief Commercial Officer & Executive VP
  • Bryan Ball, Chief Quality Officer

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among Intercept Pharmaceuticals' employees.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (2.36%), Macquarie Group Ltd. (2.10%), Geode Capital Management LLC (1.68%), Two Sigma Advisers LP (1.53%), Two Sigma Investments LP (1.53%) and Goldman Sachs Group Inc. (1.01%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, Gail Cawkwell, Jason Campagna, Mark Pruzanski, Paolo Fundaro, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends for Intercept Pharmaceuticals
.

Which major investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Goldman Sachs Group Inc., Deutsche Bank AG, Royal Bank of Canada, Macquarie Group Ltd., Duality Advisers LP, Barclays PLC, and Maverick Capital Ltd..
View insider buying and selling activity for Intercept Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Intercept Pharmaceuticals stock?

ICPT stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Balyasny Asset Management LLC, Balyasny Asset Management LLC, DLD Asset Management LP, Renaissance Technologies LLC, Marshall Wace LLP, Highbridge Capital Management LLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Intercept Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $17.23.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals has a market capitalization of $509.09 million and generates $312.69 million in revenue each year. The biopharmaceutical company earns $-274.88 million in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

Intercept Pharmaceuticals employs 498 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

Where are Intercept Pharmaceuticals' headquarters?

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards 37th FL, New York NY, 10001.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at [email protected], or via fax at 646-747-1001.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.